Findings underscore importance of prevention efforts
by boisid on Mon Jan 07, 2013 02:18 AM
Hello all and happy New Year,
For several years now I have been taking 1000 mg/day of hydroxyurea and it consistently keeps my platetlet count at around 350000. Well last year, around Q2 as I recall, my prescription plan was changed from Express Scripts to CVS Caremark. When I received my first 90 day supply of the hydroxyurea I could see that it was a different capsule color and that the generic manufacturer was different.
Fast forward around 3 or 4 months and all of a sudden my count, on 2 measurements, 1 month apart, was around 420000. I brought up the fact that the generic supplier changed and my doc said they certainly have seen changes with a change in generic manufacturers.
OK, I then proceeded to call CVS Caremark and spoke to a poharmacist. He agreed to have in my records that I only get hydroxyurea made by Teva-Barr (formerly Barr Laboratories who was acquired by Teva).
Now, after 3 months or so on the Teva-Barr product my last count, taken last week, was 352000.
So, I wanted to elt you know. I should also tell you that with Rx drugs, the FDA allows plus or minus 10-15% from what is stated as the dosage. So 1000 mg could be as low as 850-900 mg, and there is no doubt in my mind that this is what happened in my case.
I checked with a cycling firend of mine who is both a pharmacist and attorney who deals with regulatory and FDA issues. He confirmed what I stated above as to the plus/minus 10-15% issue, and he also noted that when changing from 1 manufacturer, or manufacturing site, to another it is recommended that a dose response study be initiated.
I hope this is helpful.
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.